HC Wainwright Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 294.09% from the stock’s previous close.

GANX has been the topic of several other reports. Roth Mkm reissued a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. BTIG Research restated a “buy” rating and issued a $5.00 target price on shares of Gain Therapeutics in a research note on Tuesday. Finally, Weiss Ratings lowered shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Gain Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $2.03 on Wednesday. The firm’s fifty day simple moving average is $1.82 and its 200 day simple moving average is $2.15. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34. The firm has a market capitalization of $86.58 million, a price-to-earnings ratio of -3.50 and a beta of 0.16.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). During the same period last year, the company earned ($0.16) earnings per share. As a group, equities research analysts expect that Gain Therapeutics will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GANX. Sprott Inc. acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at approximately $39,000. Commonwealth Equity Services LLC purchased a new position in shares of Gain Therapeutics during the 4th quarter valued at approximately $41,000. Millennium Management LLC acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth approximately $45,000. Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics in the fourth quarter worth $47,000. Finally, Wealthspire Advisors LLC bought a new stake in shares of Gain Therapeutics in the fourth quarter worth $54,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.